AIMS/HYPOTHESIS: We describe a novel model of insulin-deficient diabetes with a single copy of the gene encoding insulin 1 (Ins1) and no gene encoding insulin 2 (Ins2). MATERIALS AND METHODS: We constructed five lines of mice: mice with two copies of Ins1 (NOD( Ins1+/+,Ins2-/-)), mice with a single copy of Ins1 (NOD( Ins1+/-,Ins2-/-)), mice with two copies of Ins2 (NOD( Ins1-/-,Ins2+/+)), mice with a single copy of Ins2 (NOD( Ins1-/-,Ins2+/-)) and NOD( Ins1+/-,Ins2-/-) mice with a transgene encoding B16:Ala proinsulin. RESULTS: By 10 weeks of age, all male NOD( Ins1+/-,Ins2-/-) mice were diabetic, whereas all female NOD( Ins1+/-,Ins2-/-) were not diabetic (p < 0.0001). In contrast, neither male nor female NOD( Ins1-/-,Ins2+/-) with a single copy of Ins2 (rather than single copy of Ins1) developed early diabetes and no mice with two copies of either gene developed early diabetes. Islets of the diabetic male NOD( Ins1+/-,Ins2-/-) at this early age had no lymphocyte infiltration. Instead there was heterogeneous (between islet cells) weak staining for insulin. Although only male NOD( Ins1+/-,Ins2-/-) mice developed diabetes, both male and female NOD( Ins1+/-,Ins2-/-) mice had markedly decreased insulin content. In NOD( Ins1+/+,Ins2-/-), there was also a significant decrease in insulin content, whereas NOD( Ins1-/-,Ins2+/+) mice, and even NOD( Ins1-/-,Ins2+/-) mice, were normal. Male NOD( Ins1+/-,Ins2-/-) mice were completely rescued from diabetes by introduction of a transgene encoding proinsulin. On i.p. insulin tolerance testing, male mice had insulin resistance compared with female mice. CONCLUSIONS/ INTERPRETATION: These results suggest that Ins1 is a 'defective gene' relative to Ins2, and that the mouse lines created provide a novel model of sex-dimorphic insulin-deficient diabetes.
AIMS/HYPOTHESIS: We describe a novel model of insulin-deficient diabetes with a single copy of the gene encoding insulin 1 (Ins1) and no gene encoding insulin 2 (Ins2). MATERIALS AND METHODS: We constructed five lines of mice: mice with two copies of Ins1 (NOD( Ins1+/+,Ins2-/-)), mice with a single copy of Ins1 (NOD( Ins1+/-,Ins2-/-)), mice with two copies of Ins2 (NOD( Ins1-/-,Ins2+/+)), mice with a single copy of Ins2 (NOD( Ins1-/-,Ins2+/-)) and NOD( Ins1+/-,Ins2-/-) mice with a transgene encoding B16:Ala proinsulin. RESULTS: By 10 weeks of age, all male NOD( Ins1+/-,Ins2-/-) mice were diabetic, whereas all female NOD( Ins1+/-,Ins2-/-) were not diabetic (p < 0.0001). In contrast, neither male nor female NOD( Ins1-/-,Ins2+/-) with a single copy of Ins2 (rather than single copy of Ins1) developed early diabetes and no mice with two copies of either gene developed early diabetes. Islets of the diabetic male NOD( Ins1+/-,Ins2-/-) at this early age had no lymphocyte infiltration. Instead there was heterogeneous (between islet cells) weak staining for insulin. Although only male NOD( Ins1+/-,Ins2-/-) mice developed diabetes, both male and female NOD( Ins1+/-,Ins2-/-) mice had markedly decreased insulin content. In NOD( Ins1+/+,Ins2-/-), there was also a significant decrease in insulin content, whereas NOD( Ins1-/-,Ins2+/+) mice, and even NOD( Ins1-/-,Ins2+/-) mice, were normal. Male NOD( Ins1+/-,Ins2-/-) mice were completely rescued from diabetes by introduction of a transgene encoding proinsulin. On i.p. insulin tolerance testing, male mice had insulin resistance compared with female mice. CONCLUSIONS/ INTERPRETATION: These results suggest that Ins1 is a 'defective gene' relative to Ins2, and that the mouse lines created provide a novel model of sex-dimorphic insulin-deficient diabetes.
Authors: L Leroux; P Desbois; L Lamotte; B Duvillié; N Cordonnier; M Jackerott; J Jami; D Bucchini; R L Joshi Journal: Diabetes Date: 2001-02 Impact factor: 9.461
Authors: M B Soares; E Schon; A Henderson; S K Karathanasis; R Cate; S Zeitlin; J Chirgwin; A Efstratiadis Journal: Mol Cell Biol Date: 1985-08 Impact factor: 4.272
Authors: Marie K Brimnes; Teis Jensen; Trine N Jørgensen; Birgitte K Michelsen; Jesper Troelsen; Ole Werdelin Journal: J Autoimmun Date: 2002-12 Impact factor: 7.094
Authors: Maki Nakayama; Norio Abiru; Hiroaki Moriyama; Naru Babaya; Edwin Liu; Dongmei Miao; Liping Yu; Dale R Wegmann; John C Hutton; John F Elliott; George S Eisenbarth Journal: Nature Date: 2005-05-12 Impact factor: 49.962
Authors: W Chen; I Bergerot; J F Elliott; L C Harrison; N Abiru; G S Eisenbarth; T L Delovitch Journal: J Immunol Date: 2001-11-01 Impact factor: 5.422
Authors: Maki Nakayama; Hiroaki Moriyama; Norio Abiru; Sunanda R Babu; Kamila Sikora; Marcella Li; Dongmei Miao; John C Hutton; John F Elliott; George S Eisenbarth Journal: Ann N Y Acad Sci Date: 2004-12 Impact factor: 5.691
Authors: Rohit N Kulkarni; Katrine Almind; H Joseph Goren; Jonathon N Winnay; Kohjiro Ueki; Terumasa Okada; C Ronald Kahn Journal: Diabetes Date: 2003-06 Impact factor: 9.461
Authors: H Ueda; H Ikegami; E Yamato; J Fu; M Fukuda; G Shen; Y Kawaguchi; K Takekawa; Y Fujioka; T Fujisawa Journal: Diabetologia Date: 1995-05 Impact factor: 10.122
Authors: Ming Liu; Leena Haataja; Jordan Wright; Nalinda P Wickramasinghe; Qing-Xin Hua; Nelson F Phillips; Fabrizio Barbetti; Michael A Weiss; Peter Arvan Journal: PLoS One Date: 2010-10-11 Impact factor: 3.240
Authors: Israel Hodish; Ming Liu; Gautam Rajpal; Dennis Larkin; Ronald W Holz; Aaron Adams; Leanza Liu; Peter Arvan Journal: J Biol Chem Date: 2009-10-30 Impact factor: 5.157
Authors: Emilyn U Alejandro; Tatyana B Kalynyak; Farnaz Taghizadeh; Kamila S Gwiazda; Erin K Rawstron; Karen J Jacob; James D Johnson Journal: Endocrinology Date: 2010-01-07 Impact factor: 5.051
Authors: Liping Yu; Fran Dong; Dongmei Miao; Alexandra R Fouts; Janet M Wenzlau; Andrea K Steck Journal: Diabetes Care Date: 2013-02-19 Impact factor: 19.112